McKesson shares are trading lower despite reporting better-than-expected Q2 financial results and raising FY26 adjusted EPS guidance with its midpoint above estimates. The company's FY26 sales guidance midpoint is slightly above estimates, and management noted lower branded pharmaceutical pricing on its conference call.